<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators</title>
  <meta name="description" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta name="generator" content="bookdown 0.26 and GitBook 2.6.7" />

  <meta property="og:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta property="og:type" content="book" />
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  
  
  

<meta name="author" content="Adam Howes" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="introduction.html"/>
<link rel="next" href="bayes-st.html"/>
<style type="text/css">
p.abstract{
  text-align: center;
  font-weight: bold;
}
div.abstract{
  margin: auto;
  width: 90%;
}
</style>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="templates/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a>
<ul>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#acknowledgments"><i class="fa fa-check"></i>Acknowledgments</a></li>
</ul></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#chapter-overview"><i class="fa fa-check"></i><b>1.1</b> Chapter overview</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="hiv-aids.html"><a href="hiv-aids.html"><i class="fa fa-check"></i><b>2</b> The HIV/AIDS epidemic</a>
<ul>
<li class="chapter" data-level="2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#background"><i class="fa fa-check"></i><b>2.1</b> Background</a></li>
<li class="chapter" data-level="2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#surveillance"><i class="fa fa-check"></i><b>2.2</b> HIV surveillance</a>
<ul>
<li class="chapter" data-level="2.2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#data"><i class="fa fa-check"></i><b>2.2.1</b> Data</a></li>
<li class="chapter" data-level="2.2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#challenges"><i class="fa fa-check"></i><b>2.2.2</b> Challenges</a></li>
<li class="chapter" data-level="2.2.3" data-path="hiv-aids.html"><a href="hiv-aids.html#statistical-approaches"><i class="fa fa-check"></i><b>2.2.3</b> Statistical approaches</a></li>
<li class="chapter" data-level="2.2.4" data-path="hiv-aids.html"><a href="hiv-aids.html#future-directions"><i class="fa fa-check"></i><b>2.2.4</b> Future directions</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="bayes-st.html"><a href="bayes-st.html"><i class="fa fa-check"></i><b>3</b> Bayesian spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-statistics"><i class="fa fa-check"></i><b>3.1</b> Bayesian statistics</a>
<ul>
<li class="chapter" data-level="3.1.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-modelling"><i class="fa fa-check"></i><b>3.1.1</b> Bayesian modelling</a></li>
<li class="chapter" data-level="3.1.2" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-computation"><i class="fa fa-check"></i><b>3.1.2</b> Bayesian computation</a></li>
<li class="chapter" data-level="3.1.3" data-path="bayes-st.html"><a href="bayes-st.html#interplay-between-modelling-and-computation"><i class="fa fa-check"></i><b>3.1.3</b> Interplay between modelling and computation</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="bayes-st.html"><a href="bayes-st.html#spatio-temporal-statistics"><i class="fa fa-check"></i><b>3.2</b> Spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.2.1" data-path="bayes-st.html"><a href="bayes-st.html#properties-of-spatial-data"><i class="fa fa-check"></i><b>3.2.1</b> Properties of spatial data</a></li>
<li class="chapter" data-level="3.2.2" data-path="bayes-st.html"><a href="bayes-st.html#small-area-estimation"><i class="fa fa-check"></i><b>3.2.2</b> Small-area estimation</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="bayes-st.html"><a href="bayes-st.html#hierarchical-lgm-elgm"><i class="fa fa-check"></i><b>3.3</b> Model classes</a>
<ul>
<li class="chapter" data-level="3.3.1" data-path="bayes-st.html"><a href="bayes-st.html#hierarchical"><i class="fa fa-check"></i><b>3.3.1</b> Hierarchical models</a></li>
<li class="chapter" data-level="3.3.2" data-path="bayes-st.html"><a href="bayes-st.html#mixed-effects-models"><i class="fa fa-check"></i><b>3.3.2</b> Mixed effects models</a></li>
<li class="chapter" data-level="3.3.3" data-path="bayes-st.html"><a href="bayes-st.html#latent-gaussian-models"><i class="fa fa-check"></i><b>3.3.3</b> Latent Gaussian models</a></li>
<li class="chapter" data-level="3.3.4" data-path="bayes-st.html"><a href="bayes-st.html#extended-latent-gaussian-models"><i class="fa fa-check"></i><b>3.3.4</b> Extended latent Gaussian models</a></li>
</ul></li>
<li class="chapter" data-level="3.4" data-path="bayes-st.html"><a href="bayes-st.html#survey"><i class="fa fa-check"></i><b>3.4</b> Survey methods</a>
<ul>
<li class="chapter" data-level="3.4.1" data-path="bayes-st.html"><a href="bayes-st.html#survey-notation-and-key-terms"><i class="fa fa-check"></i><b>3.4.1</b> Survey notation and key terms</a></li>
<li class="chapter" data-level="3.4.2" data-path="bayes-st.html"><a href="bayes-st.html#survey-design"><i class="fa fa-check"></i><b>3.4.2</b> Survey design</a></li>
<li class="chapter" data-level="3.4.3" data-path="bayes-st.html"><a href="bayes-st.html#survey-analysis"><i class="fa fa-check"></i><b>3.4.3</b> Survey analysis</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="beyond-borders.html"><a href="beyond-borders.html"><i class="fa fa-check"></i><b>4</b> Models for spatial structure</a>
<ul>
<li class="chapter" data-level="4.1" data-path="beyond-borders.html"><a href="beyond-borders.html#background-1"><i class="fa fa-check"></i><b>4.1</b> Background</a></li>
<li class="chapter" data-level="4.2" data-path="beyond-borders.html"><a href="beyond-borders.html#models-based-on-adjacency"><i class="fa fa-check"></i><b>4.2</b> Models based on adjacency</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="beyond-borders.html"><a href="beyond-borders.html#the-besag-model"><i class="fa fa-check"></i><b>4.2.1</b> The Besag model</a></li>
<li class="chapter" data-level="4.2.2" data-path="beyond-borders.html"><a href="beyond-borders.html#best-practises-for-the-besag-model"><i class="fa fa-check"></i><b>4.2.2</b> Best practises for the Besag model</a></li>
<li class="chapter" data-level="4.2.3" data-path="beyond-borders.html"><a href="beyond-borders.html#the-reparameterised-besag-york-mollié-model"><i class="fa fa-check"></i><b>4.2.3</b> The reparameterised Besag-York-Mollié model</a></li>
<li class="chapter" data-level="4.2.4" data-path="beyond-borders.html"><a href="beyond-borders.html#concerns-about-the-besag-models-representation-of-space"><i class="fa fa-check"></i><b>4.2.4</b> Concerns about the Besag model’s representation of space</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="beyond-borders.html"><a href="beyond-borders.html#models-using-kernels"><i class="fa fa-check"></i><b>4.3</b> Models using kernels</a></li>
<li class="chapter" data-level="4.4" data-path="beyond-borders.html"><a href="beyond-borders.html#simulation-study"><i class="fa fa-check"></i><b>4.4</b> Simulation study</a></li>
<li class="chapter" data-level="4.5" data-path="beyond-borders.html"><a href="beyond-borders.html#hiv-prevalence-study"><i class="fa fa-check"></i><b>4.5</b> HIV prevalence study</a></li>
<li class="chapter" data-level="4.6" data-path="beyond-borders.html"><a href="beyond-borders.html#discussion"><i class="fa fa-check"></i><b>4.6</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="multi-agyw.html"><a href="multi-agyw.html"><i class="fa fa-check"></i><b>5</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#background-2"><i class="fa fa-check"></i><b>5.1</b> Background</a></li>
<li class="chapter" data-level="5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#data-1"><i class="fa fa-check"></i><b>5.2</b> Data</a></li>
<li class="chapter" data-level="5.3" data-path="multi-agyw.html"><a href="multi-agyw.html#model-for-risk-group-proportions"><i class="fa fa-check"></i><b>5.3</b> Model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.3.1" data-path="multi-agyw.html"><a href="multi-agyw.html#st-multinomial"><i class="fa fa-check"></i><b>5.3.1</b> Spatio-temporal multinomial logistic regression</a></li>
<li class="chapter" data-level="5.3.2" data-path="multi-agyw.html"><a href="multi-agyw.html#s-logistic"><i class="fa fa-check"></i><b>5.3.2</b> Spatial logistic regression</a></li>
<li class="chapter" data-level="5.3.3" data-path="multi-agyw.html"><a href="multi-agyw.html#female-sex-worker-population-size-adjustment"><i class="fa fa-check"></i><b>5.3.3</b> Female sex worker population size adjustment</a></li>
<li class="chapter" data-level="5.3.4" data-path="multi-agyw.html"><a href="multi-agyw.html#results"><i class="fa fa-check"></i><b>5.3.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="5.4" data-path="multi-agyw.html"><a href="multi-agyw.html#prevalence-and-incidence-by-risk-group"><i class="fa fa-check"></i><b>5.4</b> Prevalence and incidence by risk group</a>
<ul>
<li class="chapter" data-level="5.4.1" data-path="multi-agyw.html"><a href="multi-agyw.html#disaggregation-of-naomi-estimates"><i class="fa fa-check"></i><b>5.4.1</b> Disaggregation of Naomi estimates</a></li>
<li class="chapter" data-level="5.4.2" data-path="multi-agyw.html"><a href="multi-agyw.html#expected-new-infections-reached"><i class="fa fa-check"></i><b>5.4.2</b> Expected new infections reached</a></li>
<li class="chapter" data-level="5.4.3" data-path="multi-agyw.html"><a href="multi-agyw.html#results-1"><i class="fa fa-check"></i><b>5.4.3</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="5.5" data-path="multi-agyw.html"><a href="multi-agyw.html#discussion-1"><i class="fa fa-check"></i><b>5.5</b> Discussion</a>
<ul>
<li class="chapter" data-level="5.5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#limitations"><i class="fa fa-check"></i><b>5.5.1</b> Limitations</a></li>
<li class="chapter" data-level="5.5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#conclusion"><i class="fa fa-check"></i><b>5.5.2</b> Conclusion</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="naomi-aghq.html"><a href="naomi-aghq.html"><i class="fa fa-check"></i><b>6</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inference-methods"><i class="fa fa-check"></i><b>6.1</b> Inference methods</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#the-laplace-approximation"><i class="fa fa-check"></i><b>6.1.1</b> The Laplace approximation</a></li>
<li class="chapter" data-level="6.1.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#quadrature"><i class="fa fa-check"></i><b>6.1.2</b> Quadrature</a></li>
<li class="chapter" data-level="6.1.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#integrated-nested-laplace-approximation"><i class="fa fa-check"></i><b>6.1.3</b> Integrated nested Laplace approximation</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#software"><i class="fa fa-check"></i><b>6.2</b> Software</a>
<ul>
<li class="chapter" data-level="6.2.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#tmb"><i class="fa fa-check"></i><b>6.2.1</b> <code>TMB</code></a></li>
<li class="chapter" data-level="6.2.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#r-inla"><i class="fa fa-check"></i><b>6.2.2</b> <code>R-INLA</code></a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#a-universal-inla-implementation"><i class="fa fa-check"></i><b>6.3</b> A universal INLA implementation</a>
<ul>
<li class="chapter" data-level="6.3.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#epilepsy-example"><i class="fa fa-check"></i><b>6.3.1</b> Epilepsy example</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#the-naomi-model"><i class="fa fa-check"></i><b>6.4</b> The Naomi model</a>
<ul>
<li class="chapter" data-level="6.4.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#model-structure"><i class="fa fa-check"></i><b>6.4.1</b> Model structure</a></li>
<li class="chapter" data-level="6.4.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#connection-to-elgms"><i class="fa fa-check"></i><b>6.4.2</b> Connection to ELGMs</a></li>
</ul></li>
<li class="chapter" data-level="6.5" data-path="naomi-aghq.html"><a href="naomi-aghq.html#extension-of-aghq-to-moderate-dimensions"><i class="fa fa-check"></i><b>6.5</b> Extension of AGHQ to moderate dimensions</a>
<ul>
<li class="chapter" data-level="6.5.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#aghq-with-variable-levels"><i class="fa fa-check"></i><b>6.5.1</b> AGHQ with variable levels</a></li>
<li class="chapter" data-level="6.5.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#principal-components-analysis"><i class="fa fa-check"></i><b>6.5.2</b> Principal components analysis</a></li>
</ul></li>
<li class="chapter" data-level="6.6" data-path="naomi-aghq.html"><a href="naomi-aghq.html#malawi-case-study"><i class="fa fa-check"></i><b>6.6</b> Malawi case-study</a>
<ul>
<li class="chapter" data-level="6.6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#nuts-convergence"><i class="fa fa-check"></i><b>6.6.1</b> NUTS convergence</a></li>
<li class="chapter" data-level="6.6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#use-of-pca-aghq"><i class="fa fa-check"></i><b>6.6.2</b> Use of PCA-AGHQ</a></li>
<li class="chapter" data-level="6.6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#model-assessment"><i class="fa fa-check"></i><b>6.6.3</b> Model assessment</a></li>
<li class="chapter" data-level="6.6.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inference-comparison"><i class="fa fa-check"></i><b>6.6.4</b> Inference comparison</a></li>
<li class="chapter" data-level="6.6.5" data-path="naomi-aghq.html"><a href="naomi-aghq.html#exceedance-probabilities"><i class="fa fa-check"></i><b>6.6.5</b> Exceedance probabilities</a></li>
</ul></li>
<li class="chapter" data-level="6.7" data-path="naomi-aghq.html"><a href="naomi-aghq.html#discussion-2"><i class="fa fa-check"></i><b>6.7</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="conclusions.html"><a href="conclusions.html"><i class="fa fa-check"></i><b>7</b> Future work and conclusions</a>
<ul>
<li class="chapter" data-level="7.1" data-path="conclusions.html"><a href="conclusions.html#strengths"><i class="fa fa-check"></i><b>7.1</b> Strengths</a>
<ul>
<li class="chapter" data-level="7.1.1" data-path="conclusions.html"><a href="conclusions.html#chapter-refbeyond-borders"><i class="fa fa-check"></i><b>7.1.1</b> Chapter @ref(beyond-borders)</a></li>
<li class="chapter" data-level="7.1.2" data-path="conclusions.html"><a href="conclusions.html#chapter-refmulti-agyw"><i class="fa fa-check"></i><b>7.1.2</b> Chapter @ref(multi-agyw)</a></li>
<li class="chapter" data-level="7.1.3" data-path="conclusions.html"><a href="conclusions.html#chapter-refnaomi-aghq"><i class="fa fa-check"></i><b>7.1.3</b> Chapter @ref(naomi-aghq)</a></li>
</ul></li>
<li class="chapter" data-level="7.2" data-path="conclusions.html"><a href="conclusions.html#future-work"><i class="fa fa-check"></i><b>7.2</b> Future work</a></li>
<li class="chapter" data-level="7.3" data-path="conclusions.html"><a href="conclusions.html#conclusions-1"><i class="fa fa-check"></i><b>7.3</b> Conclusions</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="spatial-structure.html"><a href="spatial-structure.html"><i class="fa fa-check"></i><b>A</b> Spatial structure</a></li>
<li class="chapter" data-level="B" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html"><i class="fa fa-check"></i><b>B</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="B.1" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#the-global-aids-strategy"><i class="fa fa-check"></i><b>B.1</b> The Global AIDS Strategy</a></li>
<li class="chapter" data-level="B.2" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#household-survey-data"><i class="fa fa-check"></i><b>B.2</b> Household survey data</a></li>
<li class="chapter" data-level="B.3" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#spatial-analysis-levels"><i class="fa fa-check"></i><b>B.3</b> Spatial analysis levels</a></li>
<li class="chapter" data-level="B.4" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#survey-questions"><i class="fa fa-check"></i><b>B.4</b> Survey questions and risk group allocation</a></li>
</ul></li>
<li class="chapter" data-level="C" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html"><i class="fa fa-check"></i><b>C</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="C.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#simplified-naomi-model-description"><i class="fa fa-check"></i><b>C.1</b> Simplified Naomi model description</a>
<ul>
<li class="chapter" data-level="C.1.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#process-specification"><i class="fa fa-check"></i><b>C.1.1</b> Process specification</a></li>
<li class="chapter" data-level="C.1.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#hiv-prev"><i class="fa fa-check"></i><b>C.1.2</b> HIV prevalence</a></li>
<li class="chapter" data-level="C.1.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#art-cov"><i class="fa fa-check"></i><b>C.1.3</b> ART coverage</a></li>
<li class="chapter" data-level="C.1.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#hiv-inc"><i class="fa fa-check"></i><b>C.1.4</b> HIV incidence rate</a></li>
<li class="chapter" data-level="C.1.5" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#anc-test"><i class="fa fa-check"></i><b>C.1.5</b> ANC testing</a></li>
<li class="chapter" data-level="C.1.6" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#art-attend"><i class="fa fa-check"></i><b>C.1.6</b> ART attendance</a></li>
</ul></li>
<li class="chapter" data-level="C.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#model-assessment-1"><i class="fa fa-check"></i><b>C.2</b> Model assessment</a></li>
<li class="chapter" data-level="C.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#aghq-and-pca-aghq-details"><i class="fa fa-check"></i><b>C.3</b> AGHQ and PCA-AGHQ details</a></li>
<li class="chapter" data-level="C.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#normalising-constant-estimation"><i class="fa fa-check"></i><b>C.4</b> Normalising constant estimation</a></li>
<li class="chapter" data-level="C.5" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#inference-comparison-1"><i class="fa fa-check"></i><b>C.5</b> Inference comparison</a></li>
<li class="chapter" data-level="C.6" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#mcmc-convergence-and-suitability"><i class="fa fa-check"></i><b>C.6</b> MCMC convergence and suitability</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p>Bayesian spatio-temporal methods for small-area estimation of HIV indicators</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hiv-aids" class="section level1 hasAnchor" number="2">
<h1><span class="header-section-number">2</span> The HIV/AIDS epidemic<a href="hiv-aids.html#hiv-aids" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<!-- For PDF output, include these two LaTeX commands after unnumbered chapter headings, otherwise the mini table of contents and the running header will show the previous chapter -->
<div id="background" class="section level2 hasAnchor" number="2.1">
<h2><span class="header-section-number">2.1</span> Background<a href="hiv-aids.html#background" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is HIV -->
<p>HIV is a retrovirus which infects humans.
If untreated, HIV can develop into a more advanced stage known as acquired immunodeficiency syndrome (AIDS).
HIV primarily attacks a type of white blood cell vital for the function of the immune system.
As a result, AIDS is characterised by increased risk of developing opportunistic infections such as tuberculosis or <em>Pneumocystis</em> pneumonias.</p>
<!-- HIV is a big problem, plus how is it transmitted -->
<p>The first AIDS cases were reported in Los Angeles in the early 1980s <span class="citation">(<a href="#ref-gottlieb1981pneumocystis">Gottlieb et al. 1981</a>; <a href="#ref-barre1983isolation">Barré-Sinoussi et al. 1983</a>)</span>.
Since then, HIV has spread globally.
Transmission occurs by exposure to specific bodily fluids of an infected person.
The most common mode of transmission is via unprotected anal or vaginal sex, though transmission can also occur from a mother to her baby, or when drug injection equipment is shared.
Approximately 86 million people have become infected with HIV, and of those 40 million have died of AIDS-related causes.</p>
<!-- A lot of effort going into it -->
<p>An ongoing global and multifaceted effort has been made to respond to the epidemic.
The response has been shaped by local communities, civil society organisations, governments, research institutions, pharmaceutical companies, international agencies like the Joint United Nations Programme on HIV/AIDS (UNAIDS), and global health initiatives such like the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM).
The investment of $100 billion by PEPFAR, constituting the “largest commitment by a single nation to address a single disease in history” <span class="citation">(<a href="#ref-pepfar2022">U.S. Department of State 2022</a>)</span>, is indicative of the scale of the response.</p>

<div class="figure" style="text-align: center"><span style="display:block;" id="fig:overall-picture"></span>
<img src="figures/hiv-aids/overall-picture.png" alt="Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59% and yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% (UNAIDS 2023a). Much of the disease burden is concentrated in eastern and southern Africa, as well as western and central Africa." width="95%" />
<p class="caption">
Figure 2.1: Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59% and yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% <span class="citation">(<a href="#ref-unaids2023aidsinfo">UNAIDS 2023a</a>)</span>. Much of the disease burden is concentrated in eastern and southern Africa, as well as western and central Africa.
</p>
</div>
<!-- The effort has translated into progress -->
<p>Implementation of HIV prevention and treatment has significantly reduced the number of new HIV infections and AIDS-related deaths per year since their peak (Figure <a href="hiv-aids.html#fig:overall-picture">2.1</a>).
The most significant evidence-based interventions are:</p>
<ul>
<li>Condoms are an inexpensive and effective method for prevention of HIV and other sexually transmitted infections (STIs) such as <em>Chlamydia trachomatis</em>, <em>Neisseria gonorroeae</em>, syphilis, and <em>Trichomonas vaginalis</em>.
Condom usage has increased significantly since 1990, which is estimated to have averted 117 million new HIV infections <span class="citation">(<a href="#ref-stover2021impact">Stover and Teng 2021</a>)</span>.
That said, there remain significant and difficult to close gaps in condom usage.</li>
<li>Antiretroviral therapy (ART) is a combination of drugs which stop the virus from replicating in the body.
A person living with HIV who takes ART daily can live a full and healthy life, transforming what was once a terminal illness to a treatable chronic condition.
Of the 39 million people living with HIV (PLHIV) in 2022, around 76% were accessing ART.
A staggering 21 million AIDS-related deaths are estimated to have been averted by ART <span class="citation">(<a href="#ref-unaids2023global">UNAIDS 2023b</a>)</span>.
ART reduces the amount of virus in the blood and genital secretions.
If the virus is undetectable then there is considerable evidence that it cannot be transmitted sexually <span class="citation">(<a href="#ref-cohen2011prevention">Cohen et al. 2011</a>; <a href="#ref-broyles2023risk">Broyles et al. 2023</a>)</span>.
For this reason, in addition to providing life saving treatment, ART also operates as prevention.
Particular efforts have been made to provide pregnant women with ART to reduce the chance of mother-to-child transmission (MTCT) <span class="citation">(<a href="#ref-siegfried2011antiretrovirals">Siegfried et al. 2011</a>)</span>.</li>
<li>Voluntary medical male circumcision (VMMC) partially protects against female-to-male HIV acquisition.
Three landmark randomised control trials <span class="citation">(<a href="#ref-auvert2005randomized">Auvert et al. 2005</a>; <a href="#ref-gray2007male">Gray et al. 2007</a>; <a href="#ref-bailey2007male">Bailey et al. 2007</a>)</span> found complete surgical removal of the foreskin to result a reduction of HIV acquisition in men by 50-60%.
Based on this evidence, VMMC has been recommended since 2007 by the World Health Organization (WHO) and UNAIDS as a key HIV intervention in high-prevalence settings.
Scale up of VMMC across 15 priority countries between 2008 and 2019 is estimated to have already averted 340 thousand new HIV infections, though the future number of new HIV infections averted is likely to be much higher.</li>
<li>Pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) are antiretrovial drugs which can be taken before and after exposure to prevent transmission.
PrEP and PEP are more costly than some other prevention options, so primarily useful in high risk settings.</li>
</ul>
<p>Though important progress had been made, there remains much more to do.
In 2022, 1.3 million people were newly infected with HIV and there were 630 thousand AIDS-related deaths, more than one every minute <span class="citation">(<a href="#ref-unaids2022global">UNAIDS 2022</a>)</span>.
Bold fast-track targets have been set to accelerate the end of AIDS as global public health threat by 2030.
Renewed commitment is required to meet these targets in the context of disruption to HIV services caused by the COVID-19 pandemic and a shortfall in HIV funding <span class="citation">(<a href="#ref-economist2023triple">Economist Impact 2023</a>)</span>.</p>

<div class="figure" style="text-align: center"><span style="display:block;" id="fig:naomi-continent"></span>
<img src="figures/hiv-aids/naomi-continent.png" alt="Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. These estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS and are available from UNAIDS (2023a). White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model. Country names are given by three-leter codes as published by the International Organization for Standardization (ISO)." width="95%" />
<p class="caption">
Figure 2.2: Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. These estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS and are available from <span class="citation">UNAIDS (<a href="#ref-unaids2023aidsinfo">2023a</a>)</span>. White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model. Country names are given by three-leter codes as published by the International Organization for Standardization (ISO).
</p>
</div>
<!-- Prioritisation of interventions  -->
<p>For available resources to have the greatest impact, it is important that HIV interventions are prioritised.
Under the precision public health paradigm, the right interventions should be provided to the right populations, in the right place, at the right time <span class="citation">(<a href="#ref-khoury2016precision">Khoury, Iademarco, and Riley 2016</a>)</span>.
Some interventions might be orders of magnitude more impactful than others <span class="citation">(<a href="#ref-ord2013moral">Ord 2013</a>)</span>.</p>
<!-- Uneven burden in space -->
<p>Disease burden varies substantially across multiple spatial scales.
In some countries, the epidemic is concentrated in small populations, and national HIV prevalence is low.
In others, the epidemic is sustained by heterosexual transmission, and national HIV prevalence is higher (typically &gt;1%)
These two epidemic settings are described as concentrated and generalised respectively <span class="citation">(<a href="#ref-tanser2014concentrated">Tanser et al. 2014</a>)</span>.
Most of the countries severely affected by HIV are in sub-Saharan Africa (SSA).
It is estimated that 66% of the 39 million PLHIV worldwide live in SSA.
Adult HIV prevalence (ages 15-49) is higher than 10% (Figure <a href="hiv-aids.html#fig:naomi-continent">2.2</a>) in some countries in southern Africa.
Just as there is variation between countries, there is variation within countries.
For example, adult HIV prevalence at the district municipality level in South Africa ranges from 6% in Namakwa to 30% in uMkhanyakude.</p>
<!-- Uneven burden across people -->
<p>In all countries and contexts, some groups of people are at much higher risk than others.
Groups of people at increased risk of HIV infection are known as key populations (KPs).
Examples include men who have sex with men (MSM), female sex workers (FSW), people who inject drugs (PWID), and transgender people (TGP) <span class="citation">(<a href="#ref-stevens2022key">Stevens, Sabin, Garcia, et al. 2022</a>)</span>.
KPs are often marginalised, and face legal and social barriers.
In concentrated settings, the majority of new HIV infections occur in KPs and their sexual partners.
In generalised settings like SSA, risk is more diffuse across the population.
For example, in SSA adolescent girls and young women (AGYW) are a large demographic group at increased risk of HIV infection <span class="citation">(<a href="#ref-risher2021age">Risher et al. 2021</a>; <a href="#ref-monod2023growing">Monod et al. 2023</a>)</span>, but not typically considered a KP.</p>
<!-- Practical methods for prevention prioritisation: geographic, demographic, key population services, risk screening, individual-level risk characteristics. -->
</div>
<div id="surveillance" class="section level2 hasAnchor" number="2.2">
<h2><span class="header-section-number">2.2</span> HIV surveillance<a href="hiv-aids.html#surveillance" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is surveillance and how can it be used to meet these needs -->
<p>HIV surveillance refers to the collection, analysis, interpretation and dissemination of data relating to HIV/AIDS.
Surveillance can used to track epidemic indicators, identify at-risk populations, find drivers of transmission, and evaluate the impact of prevention and treatment programs.
Important indicators include:</p>
<ul>
<li><strong>HIV prevalence</strong> is the proportion <span class="math inline">\(\rho \in [0, 1]\)</span> of the population who have HIV, typically written as a percentage.
Both new infections and more PLHIV remaining alive by taking treatment increase HIV prevalence.
As such, HIV prevalence should not be interpreted in isolation, and is primarily used indirectly to calculate other indicators.
That said, in some circumstances when other indicators are difficult to estimate, HIV prevalence can be a useful proxy.
The number of PLHIV is given by <span class="math inline">\(N\rho\)</span>, where <span class="math inline">\(N\)</span> is the population size.</li>
<li><strong>HIV incidence</strong> is the rate <span class="math inline">\(\lambda \in \mathbb{R}\)</span> of new HIV infections, typically written as number of new infections per 1000 person years.
HIV incidence can be specified in terms of the change in HIV prevalence over some time period <span class="math inline">\(\lambda = \Delta \rho / \Delta t\)</span>.
Planning, delivery, and evaluation of prevention programming relies on estimates of HIV incidence.
The number of new HIV infections is given by <span class="math inline">\(N (1 - \rho) \lambda\)</span>.</li>
<li><strong>ART coverage</strong> is the proportion <span class="math inline">\(\alpha \in [0, 1]\)</span> of PLHIV who are on ART, typically written as a percentage.
Estimates of ART coverage play a direct role in the provision of treatment services.
The number of people taking ART is given by <span class="math inline">\(N \rho \alpha\)</span>.</li>
</ul>
<!-- * **Recently infected** -->
<!-- * **Awareness of status** -->
<!-- Key data sources used to inform these indicators are: household surveys, programmatic data -->
<div id="data" class="section level3 hasAnchor" number="2.2.1">
<h3><span class="header-section-number">2.2.1</span> Data<a href="hiv-aids.html#data" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>What are the current data?
What are the current approaches to using the data?</p>
</div>
<div id="challenges" class="section level3 hasAnchor" number="2.2.2">
<h3><span class="header-section-number">2.2.2</span> Challenges<a href="hiv-aids.html#challenges" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Obtaining reliable, timely estimates at an appropriate spatial resolution is challenging.
The most significant difficulties faced are:</p>
<ol style="list-style-type: decimal">
<li><strong>Data sparsity</strong>:
Collection of data is costly and time consuming.
As a result, limited direct data might be available for the particular time, location, and sub-population of interest.
For example, in many countries the last conducted household survey is several years out of date.</li>
<li><strong>Missing data</strong>:
The sampling frame of a survey may not correspond to the target population.
For example, many KPs are difficult to reach, and may be omitted from sampling frames.
Individuals included on the sampling frame may choose not to respond.
All surveys are subject to sampling error, as only a subset of the target population are sampled.
Each of these issues can be characterised as being problems of missing data.
I characterise missing data as referring to the shortfalls of any given study, and data sparsity as referring to limited availability of studies.</li>
<li><strong>Response and measurement biases</strong>:
Individuals may be hesitant to disclose their HIV status, or report higher risk behaviours, due to social desirability bias or a fear of discrimination or stigma.
When available, biomarker data can be used to overcome under-reporting, but still may be subject to measurement errors.</li>
<li><strong>Denominators and demography</strong>:
Many indicators are rates or proportions, which rely on estimates of the population at risk in the denominator.
Accurately estimating population denominators is itself a challenging task <span class="citation">(<a href="#ref-tatem2017worldpop">Tatem 2017</a>)</span>.
Taking a ratio of uncertain quantities amplifies uncertainty, but is rarely properly accounted for.</li>
<li><strong>Inconsistent data collection and reporting</strong>:
The types of data that are collected might vary across space and time.
Reporting protocols or definitions can also change.</li>
<li><strong>Reliance on epidemiological parameters</strong>:
Indicators rely on estimates of epidemiological parameters such as rates of disease progression.
These parameters are typically obtained from cohort studies and may not generalise to the setting of interest.
Further, they are typically applied coarsely, and without proper accounting for uncertainty.</li>
</ol>
</div>
<div id="statistical-approaches" class="section level3 hasAnchor" number="2.2.3">
<h3><span class="header-section-number">2.2.3</span> Statistical approaches<a href="hiv-aids.html#statistical-approaches" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>The challenges above make direct interpretation of the data often misleading or impossible.
Careful statistical modelling is required to overcome these limitations as best as possible.</p>
<ol style="list-style-type: decimal">
<li><strong>Borrowing information</strong>:
When little direct data are available, data judged to be indirectly related can be used to help improve estimation.
For example, if limited data are available for individuals of a certain age is a particular country, it is likely reasonable to make use of data for individuals of a similar age in that country.
As well as over age groups, information can be borrowed between and within countries, and across times.</li>
<li><strong>Evidence synthesis</strong>:
Multiple sources of evidence can be combined to overcome the limitations of any one data source.
For example, infrequently run household surveys can be complemented by up to date programmatic data.</li>
<li><strong>Expert guidance</strong>:
Expert epidemiological, demographic, and local stakeholder guidance can be used to improve estimates.
Ensuring the quality of any data used in the estimation process is essential.</li>
<li><strong>Uncertainty quantification</strong>:</li>
</ol>
</div>
<div id="future-directions" class="section level3 hasAnchor" number="2.2.4">
<h3><span class="header-section-number">2.2.4</span> Future directions<a href="hiv-aids.html#future-directions" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Aims for HIV response going forward, and the surveillance capabilities needed to meet them:</p>
<ol style="list-style-type: decimal">
<li><strong>Greater reliance on routine health system data</strong>:
It is not recommended to include HIV testing in nationally representative household surveys in low (&lt;2%) HIV prevalence settings <span class="citation">(<a href="#ref-world2005guidelines">World Health Organization 2005</a>)</span>. Patient-level HIV data systems <span class="citation">(<a href="#ref-world2017consolidated">World Health Organization 2017</a>)</span> and case-based surveillance (CBS). Integration of HIV services with other health programs and strengthening of health systems.</li>
</ol>

</div>
</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-auvert2005randomized" class="csl-entry">
Auvert, Bertran, Dirk Taljaard, Emmanuel Lagarde, Joelle Sobngwi-Tambekou, Rémi Sitta, and Adrian Puren. 2005. <span>“<span class="nocase">Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial</span>.”</span> <em>PLoS Medicine</em> 2 (11): e298.
</div>
<div id="ref-bailey2007male" class="csl-entry">
Bailey, Robert C, Stephen Moses, Corette B Parker, Kawango Agot, Ian Maclean, John N Krieger, Carolyn FM Williams, Richard T Campbell, and Jeckoniah O Ndinya-Achola. 2007. <span>“Male Circumcision for HIV Prevention in Young Men in Kisumu, Kenya: A Randomised Controlled Trial.”</span> <em>The Lancet</em> 369 (9562): 643–56.
</div>
<div id="ref-barre1983isolation" class="csl-entry">
Barré-Sinoussi, Françoise, Jean-Claude Chermann, Fran Rey, Marie Therese Nugeyre, Sophie Chamaret, Jacqueline Gruest, Charles Dauguet, et al. 1983. <span>“Isolation of a t-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS).”</span> <em>Science</em> 220 (4599): 868–71.
</div>
<div id="ref-broyles2023risk" class="csl-entry">
Broyles, Laura N, Robert Luo, Debi Boeras, and Lara Vojnov. 2023. <span>“The Risk of Sexual Transmission of HIV in Individuals with Low-Level HIV Viraemia: A Systematic Review.”</span> <em>The Lancet</em>.
</div>
<div id="ref-cohen2011prevention" class="csl-entry">
Cohen, Myron S, Ying Q Chen, Marybeth McCauley, Theresa Gamble, Mina C Hosseinipour, Nagalingeswaran Kumarasamy, James G Hakim, et al. 2011. <span>“Prevention of HIV-1 Infection with Early Antiretroviral Therapy.”</span> <em>New England Journal of Medicine</em> 365 (6): 493–505.
</div>
<div id="ref-economist2023triple" class="csl-entry">
Economist Impact. 2023. <span>“A Triple Dividend: The Health, Social and Economic Gains from Financing the HIV Response in Africa.”</span>
</div>
<div id="ref-gottlieb1981pneumocystis" class="csl-entry">
Gottlieb, Michael S, Howard M Schanker, Peng Thim Fan, Andrew Saxon, Joel D Weisman, Irving Pozalski, et al. 1981. <span>“Pneumocystis Pneumonia—Los Angeles.”</span> <em>Mmwr</em> 30 (21): 1–3.
</div>
<div id="ref-gray2007male" class="csl-entry">
Gray, Ronald H, Godfrey Kigozi, David Serwadda, Frederick Makumbi, Stephen Watya, Fred Nalugoda, Noah Kiwanuka, et al. 2007. <span>“<span class="nocase">Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial</span>.”</span> <em>The Lancet</em> 369 (9562): 657–66.
</div>
<div id="ref-khoury2016precision" class="csl-entry">
Khoury, Muin J, Michael F Iademarco, and William T Riley. 2016. <span>“Precision Public Health for the Era of Precision Medicine.”</span> <em>American Journal of Preventive Medicine</em> 50 (3): 398–401.
</div>
<div id="ref-monod2023growing" class="csl-entry">
Monod, Mélodie, Andrea Brizzi, Ronald M Galiwango, Robert Ssekubugu, Yu Chen, Xiaoyue Xi, Edward Nelson Kankaka, et al. 2023. <span>“Growing Gender Disparity in HIV Infection in Africa: Sources and Policy Implications.”</span> <em>medRxiv</em>, 2023–03.
</div>
<div id="ref-ord2013moral" class="csl-entry">
Ord, Toby. 2013. <span>“The Moral Imperative Toward Cost-Effectiveness in Global Health.”</span> <em>Center for Global Development</em> 12.
</div>
<div id="ref-risher2021age" class="csl-entry">
Risher, Kathryn A, Anne Cori, Georges Reniers, Milly Marston, Clara Calvert, Amelia Crampin, Tawanda Dadirai, et al. 2021. <span>“Age Patterns of HIV Incidence in Eastern and Southern Africa: A Modelling Analysis of Observational Population-Based Cohort Studies.”</span> <em>The Lancet HIV</em> 8 (7): e429–39.
</div>
<div id="ref-siegfried2011antiretrovirals" class="csl-entry">
Siegfried, Nandi, Lize van der Merwe, Peter Brocklehurst, and Tin Tin Sint. 2011. <span>“Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV Infection.”</span> <em>Cochrane Database of Systematic Reviews</em>, no. 7.
</div>
<div id="ref-stevens2022key" class="csl-entry">
Stevens, Oliver, Keith Sabin, Sonia Arias Garcia, Rebecca Anderson, Kalai Willis, Abu Abdul-Quader, Anne McIntyre, et al. 2022. <span>“Key Population Size, HIV Prevalence, and ART Coverage in Sub-Saharan Africa: Systematic Collation and Synthesis of Survey Data.”</span> <em>medRxiv</em>, 2022–07.
</div>
<div id="ref-stover2021impact" class="csl-entry">
Stover, John, and Yu Teng. 2021. <span>“The Impact of Condom Use on the HIV Epidemic.”</span> <em>Gates Open Research</em> 5.
</div>
<div id="ref-tanser2014concentrated" class="csl-entry">
Tanser, Frank, Tulio de Oliveira, Mathieu Maheu-Giroux, and Till Bärnighausen. 2014. <span>“Concentrated HIV Sub-Epidemics in Generalized Epidemic Settings.”</span> <em>Current Opinion in HIV and AIDS</em> 9 (2): 115.
</div>
<div id="ref-tatem2017worldpop" class="csl-entry">
Tatem, Andrew J. 2017. <span>“WorldPop, Open Data for Spatial Demography.”</span> <em>Scientific Data</em> 4 (1): 1–4.
</div>
<div id="ref-unaids2022global" class="csl-entry">
UNAIDS. 2022. <span>“In Danger: UNAIDS Global AIDS Update 2022.”</span> <a href="https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update" class="uri">https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update</a>.
</div>
<div id="ref-unaids2023aidsinfo" class="csl-entry">
———. 2023a. <span>“<span class="nocase">AIDSinfo: Global data on HIV epidemiology and response</span>.”</span> <a href="https://aidsinfo.unaids.org/" class="uri">https://aidsinfo.unaids.org/</a>.
</div>
<div id="ref-unaids2023global" class="csl-entry">
———. 2023b. <span>“The Path That Ends AIDS: UNAIDS Global AIDS Update 2023.”</span> <a href="https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023" class="uri">https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023</a>.
</div>
<div id="ref-pepfar2022" class="csl-entry">
U.S. Department of State. 2022. <span>“<span>Latest Global Program Results</span>.”</span> <a href="https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf" class="uri">https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf</a>.
</div>
<div id="ref-world2005guidelines" class="csl-entry">
World Health Organization. 2005. <span>“Guidelines for Measuring National HIV Prevalence in Population-Based Surveys.”</span>
</div>
<div id="ref-world2017consolidated" class="csl-entry">
———. 2017. <span>“Consolidated Guidelines on Person-Centred HIV Patient Monitoring and Case Surveillance.”</span>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="introduction.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="bayes-st.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": false,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": false
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/ulyngs/oxforddown/tree/master/02-hiv-aids.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
